Your Complete Transition Guide Between Weight Management Treatments
Understanding The Transition When Moving From Wegovy To Mounjaro
Moving from Wegovy to Mounjaro requires understanding fundamental differences in their mechanisms and starter dose protocols. Wegovy utilises semaglutide, a GLP-1 receptor agonist, whilst Mounjaro contains tirzepatide, which targets both GIP and GLP-1 receptors simultaneously. This dual-action approach means the starter dose requirements differ significantly between the treatments. Wegovy's gentle 0.25mg starting dose allows gradual tolerance building over four weeks, whilst Mounjaro begins at 2.5mg with its own escalation schedule.
The transition timing between these prescription-only medicines requires careful clinical consideration. Your prescriber will evaluate your current Wegovy response, any experienced side effects, and overall treatment goals before recommending the switch. Both treatments are available through EverydayMeds' GPhC-registered pharmacy #9012878, ensuring continuity of care throughout your transition. The clinical assessment process remains consistent whether you're starting fresh or transitioning between treatments, maintaining safety and regulatory compliance.
Starter Dose Pricing And Value Comparison For Treatment Transition
When moving from Wegovy to Mounjaro, understanding the cost implications of restarting with a new starter dose protocol is essential. Wegovy's 0.25mg starter dose costs £79.99 for new customers using code FIRST40 at checkout, covering weeks 1-4 of treatment. For those wanting convenience during transition, the Intro Duo bundle provides both 0.25mg and 0.5mg doses for £169.99, ensuring seamless progression through the first two dose levels. This approach eliminates the need for multiple orders during your initial treatment months.
Mounjaro's pricing structure differs due to its distinct dosing schedule, starting at 2.5mg rather than the lower microgram doses used in Wegovy. Both treatments require the same clinical assessment process and next-day cold-chain delivery to maintain medication integrity. EverydayMeds offers both options with identical prescription standards, allowing your prescriber to recommend the most suitable treatment based on your individual circumstances rather than cost considerations alone.
Clinical Evidence Supporting Moving From Wegovy To Mounjaro Decisions
The clinical evidence supporting both treatments comes from separate, robust trial programmes that cannot be directly compared due to different study designs and participant populations. Wegovy's efficacy was demonstrated in the STEP trial series, with STEP 1 showing patients achieved an average of approximately clinically studied weight loss at 68 weeks when used alongside a reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). These results support Wegovy's role in comprehensive weight management programmes under clinical supervision.
Mounjaro's clinical programme demonstrates the potential benefits of dual GIP and GLP-1 receptor activation, though direct comparison of trial outcomes isn't appropriate due to differing methodologies and endpoints. Both treatments represent evidence-based approaches to weight management, and the choice between them should be based on individual patient factors rather than head-to-head efficacy comparisons. Your prescriber can evaluate which mechanism may be more suitable for your specific circumstances.
How Wegovy Works During The Starter Dose Period
Wegovy's 0.25mg starter dose introduces semaglutide gradually to minimise initial side effects whilst establishing the therapeutic foundation. As a GLP-1 receptor agonist, semaglutide mimics the natural incretin hormone that signals satiety to your brain after eating. During the first four weeks, you may notice reduced appetite, earlier feelings of fullness, and potentially decreased food cravings as the medication begins influencing your appetite regulation centres. The starter dose is specifically calibrated to allow your digestive system to adjust to the treatment whilst building tolerance for future dose increases. This gentle introduction phase is crucial for long-term treatment success and helps establish sustainable eating patterns alongside the prescribed reduced-calorie diet and increased physical activity programme.
Streamlined Ordering Process When Moving From Wegovy To Mounjaro
EverydayMeds simplifies the process of moving from Wegovy to Mounjaro through our comprehensive clinical assessment system. The 3-minute online questionnaire captures your current treatment history, including your Wegovy experience, any side effects encountered, and your treatment goals with the new medication. Our prescribers review your assessment within 3 working days (or 24 hours with express review) to determine suitability for Mounjaro's starter dose protocol. Once approved, your medication ships via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. This seamless process ensures minimal treatment gaps when transitioning between weight management medications under proper clinical supervision.
Storage Considerations During Treatment Transitions
Storage requirements differ between Wegovy and Mounjaro, affecting travel and lifestyle planning during your transition period. Wegovy offers superior room temperature stability, maintaining effectiveness for up to 6 weeks when stored below 30°C after removal from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both treatments require initial refrigerated storage at 2-8°C before first use, and both utilise pre-filled pen devices for convenient weekly injections. The FlexTouch pen system used with Wegovy provides clear dose confirmation and user-friendly operation throughout the 16-week dose escalation schedule. Understanding these practical differences helps ensure treatment continuity whether you're at home or travelling during your weight management journey.
Personalised Approach To Moving From Wegovy To Mounjaro Starter Dosing
The decision to move from Wegovy to Mounjaro often stems from individual responses to treatment, side effect profiles, or desire to explore dual receptor activation mechanisms. Your prescriber evaluates multiple factors including your current weight management progress, tolerance to GLP-1 medications, and any specific challenges experienced with Wegovy. This personalised assessment ensures the Mounjaro starter dose protocol aligns with your clinical history and treatment objectives.
EverydayMeds' prescribers understand that moving from Wegovy to Mounjaro isn't simply about switching medications—it's about optimising your weight management strategy. The clinical team considers your previous dose escalation experience, response patterns, and lifestyle factors when recommending the transition approach. This individualised care ensures your new treatment protocol supports your long-term health goals whilst maintaining the highest safety standards.
Expert Support Throughout Your Treatment Transition
Moving from Wegovy to Mounjaro with EverydayMeds means access to ongoing clinical support throughout your transition. Our prescribers provide guidance on timing the switch, managing any overlap periods, and what to expect during Mounjaro's initial weeks. The clinical team understands the nuances of transitioning between different weight management medications and can address specific concerns about restarting with a new mechanism of action. Both Wegovy and Mounjaro are available from EverydayMeds—your prescriber can help determine which treatment aligns with your current needs and health objectives. Take your clinical assessment today to explore your options, with new customer code FIRST40 and returning customer code DOSE25 available at checkout for optimal pricing on either treatment pathway.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
